Evolus Q4 revenue $34.7M (+68% YoY); 2021 revenue $99.7M (+76%); 2022 guidance $143-150M reaffirmed

Evolus, Inc.

Q4 2021 net revenue $34.7M, up 68% from Q4 2020; full-year revenue $99.7M, up 76% over 2020.
Cash and cash equivalents $146.3M at Dec 31, 2021, including $68.7M from first tranche of $125M term loan.
Reaffirmed FY2022 revenue guidance of $143-150M (43-50% YoY growth); expects adjusted gross margin 58-61%.
Added 400 new accounts in Q4 and 1,400 in 2021; total accounts >7,000 with reorder rate >70%.
Phase II extra-strength Jeuveau study on track for first patient Q1 2022; Nuceiva EU launch planned Q3 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.